tiprankstipranks
Advertisement
Advertisement

NKTX Stock Latest News

Nkarta (NKTX): Constructive Buy Rating on Leadership, Strategic Positioning, and Upcoming Value-Creating Milestones
RatingsNkarta (NKTX): Constructive Buy Rating on Leadership, Strategic Positioning, and Upcoming Value-Creating Milestones
3d ago
NKTX
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
PremiumThe Fly
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
4d ago
NKTX
Nkarta price target lowered to $12 from $14 at Mizuho
PremiumThe Fly
Nkarta price target lowered to $12 from $14 at Mizuho
19d ago
NKTX
Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
PremiumRatings
Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
23d ago
NKTX
Nkarta price target raised to $11 from $10 at Needham
PremiumThe Fly
Nkarta price target raised to $11 from $10 at Needham
24d ago
NKTX
Nkarta Launches $100 Million At-the-Market Stock Offering
PremiumCompany AnnouncementsNkarta Launches $100 Million At-the-Market Stock Offering
24d ago
8K
NKTX
Nkarta files $350M mixed securities shelf
Premium
The Fly
Nkarta files $350M mixed securities shelf
25d ago
NKTX
Nkarta reports Q4 EPS (37c), consensus (29c)
Premium
The Fly
Nkarta reports Q4 EPS (37c), consensus (29c)
25d ago
NKTX
Is NKTX a Buy, Before Earnings?
PremiumPre-Earnings
Is NKTX a Buy, Before Earnings?
1M ago
NKTX
Nkarta price target lowered to $11 from $12 at Stifel
PremiumThe Fly
Nkarta price target lowered to $11 from $12 at Stifel
5M ago
NKTX
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
PremiumRatings
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
5M ago
NKTX
Nkarta Advances NKX019 Program Amid Financial Stability
PremiumCompany Announcements
Nkarta Advances NKX019 Program Amid Financial Stability
5M ago
NKTX
Nkarta reports Q3 EPS (29c), consensus (30c)
PremiumThe FlyNkarta reports Q3 EPS (29c), consensus (30c)
5M ago
NKTX
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
Premium
Company Announcements
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
6M ago
NKTX
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
Premium
Company Announcements
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
6M ago
NKTX
Nkarta price target lowered to $12 from $14 at Stifel
PremiumThe Fly
Nkarta price target lowered to $12 from $14 at Stifel
8M ago
NKTX
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
PremiumRatings
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
8M ago
NKTX
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
PremiumRatings
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
8M ago
NKTX
Nkarta, Inc. Reports Q2 2025 Financial Results
PremiumCompany Announcements
Nkarta, Inc. Reports Q2 2025 Financial Results
8M ago
NKTX
Strategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects
PremiumRatingsStrategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects
8M ago
NKTX
Nkarta reports Q2 EPS (31c), consensus (35c)
Premium
The Fly
Nkarta reports Q2 EPS (31c), consensus (35c)
8M ago
NKTX
Nkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating
Premium
Ratings
Nkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating
9M ago
NKTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >